Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Diagnostic and Therapeutic Applications of Microarrays in Liver Transplantation

NCT03193151 · View on ClinicalTrials.gov ↗

Study Summary

INTERLIVER is a prospective observational study of the relationship of the molecular phenotype of 300 liver transplant biopsies to the histologic phenotype and the clinical features and outcomes. A segment of a biopsy performed as standard-of-care for indications, or by center protocol, will be used for gene expression study.

Conditions Studied

Interventions

  • PROCEDURE liver biopsy

Study Locations (15)

Other

  • Centenary Institute of Cancer Medicine & Cell Biology, Royal Prince Alfred Hospital — Camperdown
  • Dep. of Nephrology, Transplantation & Internal Med., Samodzielny Publiczny Szpital Kliniczny im. A. Mieleckiego — Katowice
  • Independent Public Composite Regional Hospital — Szczecin
  • Warsaw Medical University, Jesus the Child Clinical Hospital — Warsaw
  • Warsaw Medical University, Independent Public Clinical Hospital — Warsaw
  • Institute for Liver Science, King's College London — London

California

  • University of California San Francisco, Transplant Research Unit — San Francisco

Illinois

  • Northwestern Memorial Hospital — Chicago

Maryland

  • University of Maryland School of Medicine — Baltimore

Michigan

  • Henry Ford Transplant Institute — Detroit

Tennessee

  • Vanderbilt University Medical Center, Vanderbilt Transplant Center — Nashville

Texas

  • Baylor University Medical Center, Annette C. and Harold C. Simmons Transplant Institute — Dallas

Virginia

  • Transplant Surgery, VCU Medical Center — Richmond

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2017-12-19
Est. Completion 2027-12

Sponsor

University of Alberta

135 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03193151

The ClinicalTrials.gov registry entry for NCT03193151 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alberta, which has 135 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Liver Dysfunction appearing as the primary indexed condition, and to 1 intervention — of which liver biopsy is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03193151 reports 15 study locations spanning 10 distinct geographic areas — top geographies include Other, California, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03193151 about?

NCT03193151 is a clinical study titled "Diagnostic and Therapeutic Applications of Microarrays in Liver Transplantation". INTERLIVER is a prospective observational study of the relationship of the molecular phenotype of 300 liver transplant biopsies to the histologic phenotype and the clinical features and outcomes. A segment of a biopsy performed as standard-of-care for indications, or by center protocol, will be used...

What is the current status of trial NCT03193151?

This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2017-12-19. Estimated completion is 2027-12.

What conditions does trial NCT03193151 study?

This clinical trial studies the following conditions: Liver Dysfunction. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03193151?

The interventions under investigation include: liver biopsy (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03193151?

This trial is sponsored by University of Alberta, which has 135 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03193151 being conducted?

This trial has 15 study locations across California, Illinois, Maryland, Michigan, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial